A triplet regimen extended OS compared with the current standard of care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.
Patients with multiple myeloma often become refractory to first-line triplet or quadruplet therapy regimens, creating a need for effective second- or later-line treatments.
The randomized phase 3 DREAMM-7 trial compared the efficacy of a three-drug experimental regimen — the antibody-drug conjugate belantamab mafodotin (Blenrep, GSK) plus bortezomib and dexamethasone (BVd) — with the current standard of care,
